The stock of Acadia Pharmaceuticals Inc (ACAD) has seen a -1.07% decrease in the past week, with a 2.46% gain in the past month, and a 8.52% flourish in the past quarter. The volatility ratio for the week is 2.87%, and the volatility levels for the past 30 days are at 4.14% for ACAD. The simple moving average for the past 20 days is -3.08% for ACAD’s stock, with a 1.70% simple moving average for the past 200 days.
Is It Worth Investing in Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Right Now?
The price-to-earnings ratio for Acadia Pharmaceuticals Inc (NASDAQ: ACAD) is 21.61x, which is above its average ratio. Moreover, the 36-month beta value for ACAD is 0.40. Analysts have varying opinions on the stock, with 7 analysts rating it as a “buy,” 6 as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for ACAD is 164.30M and currently, short sellers hold a 5.70% of that float. On December 31, 2024, ACAD’s average trading volume was 1.43M shares.
ACAD) stock’s latest price update
Acadia Pharmaceuticals Inc (NASDAQ: ACAD)’s stock price has plunge by -1.53relation to previous closing price of 16.95. Nevertheless, the company has seen a -1.07% plunge in its stock price over the last five trading sessions. businesswire.com reported 2024-12-19 that SAN DIEGO–(BUSINESS WIRE)–Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive Officer will represent the Company in a session scheduled on Tuesday, January 14, 2025, at 9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time. A live webcast of Acadia’s presentation will be accessible on the company’s website, Acadia.com, under the investors section and an archi.
Analysts’ Opinion of ACAD
Morgan Stanley, on the other hand, stated in their research note that they expect to see ACAD reach a price target of $20, previously predicting the price at $28. The rating they have provided for ACAD stocks is “Equal-Weight” according to the report published on August 07th, 2024.
BMO Capital Markets gave a rating of “Outperform” to ACAD, setting the target price at $31 in the report published on June 27th of the current year.
ACAD Trading at 1.64% from the 50-Day Moving Average
After a stumble in the market that brought ACAD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.71% of loss for the given period.
Volatility was left at 4.14%, however, over the last 30 days, the volatility rate increased by 2.87%, as shares surge +2.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.02% upper at present.
During the last 5 trading sessions, ACAD fell by -1.07%, which changed the moving average for the period of 200-days by -10.89% in comparison to the 20-day moving average, which settled at $17.22. In addition, Acadia Pharmaceuticals Inc saw -46.69% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACAD starting from Teehan Brendan, who sale 10,329 shares at the price of $16.81 back on Nov 19 ’24. After this action, Teehan Brendan now owns 62,105 shares of Acadia Pharmaceuticals Inc, valued at $173,630 using the latest closing price.
Kihara James, the PRINCIPAL ACCOUNTING OFFICER of Acadia Pharmaceuticals Inc, sale 4,073 shares at $16.81 during a trade that took place back on Nov 19 ’24, which means that Kihara James is holding 19,863 shares at $68,467 based on the most recent closing price.
Stock Fundamentals for ACAD
Current profitability levels for the company are sitting at:
- 0.12 for the present operating margin
- 0.92 for the gross margin
The net margin for Acadia Pharmaceuticals Inc stands at 0.14. The total capital return value is set at 0.18. Equity return is now at value 27.36, with 15.97 for asset returns.
Based on Acadia Pharmaceuticals Inc (ACAD), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at 5.02.
Currently, EBITDA for the company is -67.83 million with net debt to EBITDA at -0.87. When we switch over and look at the enterprise to sales, we see a ratio of 2.87. The receivables turnover for the company is 9.46for trailing twelve months and the total asset turnover is 0.95. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.29.
Conclusion
To wrap up, the performance of Acadia Pharmaceuticals Inc (ACAD) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
